The inhibition of AChE is a crucial therapeutic target in the management of neurodegenerative disorders, such as Alzheimer’s disease, due to the fundamental role of this enzyme in regulating cholinergic neurotransmission by hydrolyzing acetylcholine at neuronal synapses [41]. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.